Targeting human serum fucome by an integrated liquid-phase multicolumn platform operating in "cascade" to facilitate comparative mass spectrometric analysis of disease-free and breast cancer sera

• Published in: Proteomics (Weinheim) 2013-05, Vol.13 (10-11), p.1701-1713
• Main Authors: Selvaraju, Subhashini, Rassi, Ziad El
• Format: Article
• Language: English
• Subjects: Affinity chromatography; Biomarkers, Tumor - blood; Biomarkers, Tumor - isolation & purification; Breast cancer; Breast Neoplasms - blood; Case-Control Studies; Chromatography, Affinity; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Differential protein expression; Female; Fucose - blood; Glycoproteins - blood; Glycoproteins - isolation & purification; Glycoproteomics; Humans; Lectins - chemistry; Multidimensional LC; Proteome - isolation & purification; Proteome - metabolism; Tandem Mass Spectrometry
• ISSN: 1615-9853; 1615-9861
• DOI: 10.1002/pmic.201200524

A fully integrated platform was developed for capturing/fractionating human fucome from disease‐free and breast cancer sera. It comprised a multicolumn operated by HPLC pumps and switching valves for the simultaneous depletion of high abundance proteins via affinity‐based subtraction and the capturing of fucosylated glycoproteins via lectin affinity chromatography followed by the fractionation of the captured glycoproteins by reversed phase chromatography (RPC). Two lectin columns specific to fucose, namely Aleuria aurantia lectin (AAL) and Lotus tetragonolobus agglutinin (LTA) were utilized. The platform allowed the “cascading” of the serum sample from column‐to‐column in the liquid phase with no sample manipulation between the various steps. This guaranteed no sample loss and no propagation of experimental biases between the various columns. Finally, the fucome was fractionated by RPC yielding desalted fractions in volatile acetonitrile‐rich mobile phase, which after vacuum evaporation were subjected to trypsinolysis for LC‐MS/MS analysis. This permitted the identification of the differentially expressed proteins (DEP) in breast cancer serum yielding a broad panel of 35 DEP from the combined LTA and AAL captured proteins and a narrower panel of eight DEP that were commonly differentially expressed in both LTA and AAL fractions, which are considered as more representative of cancer altered fucome.